Protease-activated receptor-1 (PAR1) is a G-protein-coupled receptor (GPCR) for the coagulant protease thrombin. Similar to other GPCRs, PAR1 is promiscuous and couples to multiple heterotrimeric G-protein subtypes in the same cell and promotes diverse cellular responses. The molecular mechanism by which activation of a given GPCR with the same ligand permits coupling to multiple G-protein subtypes is unclear. Here, we report that N-linked glycosylation of PAR1 at extracellular loop 2 (ECL2) controls G 12/13 versus G q coupling specificity in response to thrombin stimulation. A PAR1 mutant deficient in glycosylation at ECL2 was more effective at stimulating G q -mediated phosphoinositide signaling compared with glycosylated wildtype receptor. In contrast, wildtype PAR1 displayed a greater efficacy at G 12/13 -dependent RhoA activation compared with mutant receptor lacking glycosylation at ECL2. Endogenous PAR1 rendered deficient in glycosylation using tunicamycin, a glycoprotein synthesis inhibitor, also exhibited increased PI signaling and diminished RhoA activation opposite to native receptor. Remarkably, PAR1 wildtype and glycosylation-deficient mutant were equally effective at coupling to G i and β-arrestin-1. Consistent with preferential G 12/13 coupling, thrombinstimulated PAR1 wildtype strongly induced RhoA-mediated stress fiber formation compared with mutant receptor. In striking contrast, glycosylation-deficient PAR1 was more effective at increasing cellular proliferation, associated with G q signaling, than wildtype receptor. These studies suggest that N-linked glycosylation at ECL2 contributes to the stabilization of an active PAR1 state that preferentially couples to G 12/13 versus G q and defines a previously unidentified function for N-linked glycosylation of GPCRs in regulating G-protein signaling bias.
thrombin | GPCR | arrestin | endothelial | RhoA P rotease-activated receptor-1 (PAR1) is the prototypical member of a family of four G-protein-coupled receptors (GPCRs) that are activated by specific proteases including the coagulant protease thrombin. Thrombin is generated during vascular injury and inflammation and promotes hemostasis, thrombosis, and inflammatory and proliferative responses (1) . PAR1 is crucial for thrombinelicited responses in cell types such as human platelets, fibroblasts, and endothelial cells and accordingly is an important drug target for vascular and thrombotic diseases (2) . PAR1 has also been implicated in progression of certain malignant cancers (3) .
Thrombin activates PAR1 through proteolytic cleavage of the extracellular N terminus, which unmasks a new N-terminal domain that acts as a tethered ligand that binds intramolecularly to the receptor to induce transmembrane signaling (4, 5) . A synthetic peptide that mimics the first six residues of the newly formed N terminus, SFLLRN, can activate PAR1 independent of thrombin and receptor cleavage. Several studies indicate that residues within the tethered ligand sequence interact specifically with residues in the extracellular loop 2 (ECL2) of PAR1 to facilitate receptor activation (6, 7) . The high-resolution crystal structure of PAR1 bound to the antagonist vorapaxar also reveals a superficial hydrophobic binding pocket close to the extracellular surface (8) . These studies suggest that the PAR1 tethered ligand likely binds superficially to ECL2 to induce conformational changes sufficient for receptor activation.
Once activated by thrombin, PAR1 couples to multiple heterotrimeric G-protein subtypes concomitantly in the same cell. PAR1 stimulates phospholipase C-catalyzed hydrolysis of phosphoinositides (PI) through G q and inhibits adenylyl cyclase through G i at the same time (9) . Concurrently, PAR1 couples to G 12/13 , leading to activation of Rho guanine nucleotide exchange factors and RhoA signaling (10) . Similar to other GPCRs, the intracellular loop 2 (ICL2) and putative eighth helix have been implicated in PAR1 interaction with G proteins (11, 12) . In addition, particular residues within ICL2 appear to dictate PAR1-G-protein subtype coupling specificity (13) . However, it remains unclear how the tethered ligand of PAR1 generated by thrombin cleavage might interact differently with the receptor to specify unique coupling to distinct G-protein subtypes in the same cell.
GPCRs are dynamic molecules that assume different conformational states. Consequently, different ligands can stabilize unique active conformations of the same GPCR and facilitate activation of distinct signaling effectors such as G proteins or β-arrestins (14, 15) . This process is termed biased agonism or functional selectivity. Quantification of GPCR signaling bias has also been shown to describe the effects of receptor mutation on the relative interactions Significance G-protein-coupled receptors (GPCRs) are the largest class of mammalian signaling receptors and mediate vast physiological responses. The capacity to modulate GPCR signaling therapeutically is important for treatment of various diseases, and discovering new aspects of receptor signaling is critical for drug development. Protease-activated receptor-1 (PAR1) is GPCR for thrombin. Similar to other GPCRs, PAR1 is promiscuous and couples to multiple heterotrimeric G-protein subtypes in the same cell. How a single GPCR can couple to multiple G-protein subtypes concurrently has remained an enigma. We demonstrate that N-linked glycosylation of PAR1 regulates G-protein coupling specificity and differentially controls cellular responses. Thus, the status of GPCR glycosylation is a critical determinant for specifying coupling to distinct G-protein subtypes.
with signaling effectors (16, 17) . Besides binding of ligands to allosteric sites on the receptor, GPCR interaction with other proteins and segregation into plasma membrane microdomains have been reported to affect receptor bias toward particular effectors. However, whether posttranslational modification of a given GPCR affects ligand-induced coupling to distinct signaling effectors is not known. Here, we report that asparagine (N)-linked glycosylation of PAR1 at ECL2 regulates G 12/13 -versus G q -protein coupling specificity, which modulates the robustness of thrombin-induced G 12/13 -dependent RhoA mediated stress fiber formation and cellular proliferation associated with G q signaling in fibroblasts. These findings are the first, to our knowledge, to define a function for N-linked glycosylation of a GPCR in regulating G-protein signaling bias.
Results

PAR1
Deficient in Glycosylation at ECL2 Exhibits Enhanced G q -Mediated PI Signaling. PAR1 containing amino acid Asn250Ala and Asn259Ala mutations that lacks N-linked glycosylation at ECL2, designated NA ECL2, displayed a greater capacity to stimulate PI hydrolysis compared with wildtype (WT) receptor following exposure to thrombin in HeLa cells (18) . Similar differences in thrombin-induced PI hydrolysis were observed in COS-7 cells transiently expressing comparable levels of cell surface PAR1 WT and NA ECL2 mutant ( Fig.  S1 A and B) . To determine whether activated PAR1 coupling to G q protein specifically mediates enhanced PI signaling, siRNA was used to deplete cells of Gα q expression (Fig. 1A) . HeLa cells stably expressing PAR1 WT and NA ECL2 mutant were transfected with nonspecific or Gα q -specific siRNAs and labeled with myo-[ 3 H]inositol. Thrombin stimulated a greater increase in PI hydrolysis in PAR1 NA ECL2 cells compared with WT cells transfected with nonspecific siRNA that was not due to differences in receptor expression ( Fig. 1 A and B) . However, both PAR1 WT and NA ECL2 cells deficient in Gα q expression failed to elicit a thrombin response (Fig. 1A) , indicating that activated PAR1-induced PI hydrolysis is mediated by G q in HeLa cells.
To determine if glycosylation of PAR1 at ECL2 affects G q -stimulated PI signaling by modulating receptor association with Gα q protein, we performed coimmunoprecipitation (co-IP) assays. HeLa cells stably expressing PAR1 WT or NA ECL2 mutant were transiently transfected with different amounts of 3 H]inositol were stimulated with 10 nM α-Th. Data (mean ± SD; n = 3) are from three independent experiments and were significant (***P < 0.001). (B) PAR1 surface expression (mean ± SD; n = 3) was determined by ELISA. Control (Ctrl) is secondary antibody only. (Inset) Immunoblots of cell lysates. (C) FLAG-PAR1 WT or FLAG-NA ECL2 mutant HeLa cells transiently transfected with HA-Gα q were lysed, immunoprecipitated, and immunoblotted as indicated. Data (mean ± SD; n = 3) are from three independent experiments and were significant (**P < 0.01). (D) FLAG-PAR1 WT or FLAG-NA ECL2 mutant HeLa cells transfected with HA-Gα q or untransfected (UT) cells were treated with 10 nM α-Th, lysed, immunoprecipitated, and immunoblotted as indicated. Data (mean ± SEM; n = 4) are from four independent experiments and were significant (*P < 0.01).
Gα q plasmid. PAR1 was immunoprecipitated, and coassociated Gα q was detected by immunoblotting. PAR1 NA ECL2 exhibited a greater capacity to co-IP with Gα q basally compared with WT receptor or IgG control (Fig. 1C , lanes 1, 4, and 7). Remarkably, thrombin induced a twofold increase in PAR1 WT-Gα q association compared with control cells (Fig. 1D, lanes 1-3) . Although PAR1 NA ECL2 mutant exhibited a statistically greater capacity to interact with Gα q basally ( Fig. 1 C and D) , receptor-Gα q coassociation was not further increased by thrombin stimulation (Fig. 1D , lanes 4 and 5). The PAR1 NA ECL2 mutant expressed in COS-7 cells also showed enhanced association with Gα q protein compared with WT receptor (Fig. S1C) , indicating that the observed findings are not cell type specific.
In many cell types, PAR1 and G q localize to caveolae (19, 20) , plasma membrane lipid rafts enriched in cholesterol and caveolin-1. To exclude the possibility that altered PAR1 WT versus NA ECL2 mutant activation of G q protein might be due to differential localization in caveolae, sucrose gradient fractionation was used. A similar distribution of PAR1 WT, NA ECL2, and G q proteins in caveolin-1 enriched and nonenriched fractions was observed (Fig. S1D ). These data suggest that thrombin-activated PAR1 lacking glycosylation at ECL2 displays an enhanced capacity to couple to G q -dependent PI signaling in different cell types that is not due to alterations in receptor expression or distribution to caveolae. To examine whether glycosylation at ECL2 regulates PAR1 coupling to other G-protein subtypes, we examined RhoA activation, an effector of G 12/13 proteins. HeLa cells stably expressing comparable PAR1 WT and NA ECL2 at the cell surface were stimulated with thrombin, and activation of RhoA was measured using GST-rhotekin Rho-binding domain (RBD) pull-down assays (21) . Thrombin induced a robust increase in RhoA activation at 2.5 min in PAR1 WT cells that subsided after 15-30 min ( Fig. 2A , lanes 3-6), whereas untransfected cells not expressing PAR1 were not responsive ( Fig. 2A, lanes 1 and 2) . In contrast, RhoA activation was significantly reduced in thrombin-treated PAR1 NA ECL2 cells examined over the same time frame ( Fig. 2A, lanes 3-10) . Consistent with these findings, activated PAR1 WT was more potent at stimulating RhoA activation than the NA ECL2 mutant assessed at earlier time points (Fig. S2A ). The peptide agonist SFLLRN also significantly increased RhoA activation in PAR1 WT cells compared with NA ECL2 expressing cells (Fig. 2B , lanes 4-9), indicating that neither thrombin binding nor proteolytic cleavage contribute to differential RhoA activation. Compared with PAR1 NA ECL2 mutant, RhoA activation induced by thrombin-activated PAR1 WT was also markedly increased in COS-7 cells (Fig. S2B ). These data suggest that activated PAR1 WT has a greater capacity to induce RhoA signaling compared to mutant receptor deficient in glycosylation at ECL2.
To determine if the differences in RhoA activation exhibited by PAR1 WT versus NA ECL2 mutant are mediated by G 12/13 proteins, siRNAs were used to deplete cells of Gα 12 and/or Gα 13 expression. PAR1 WT and NA ECL2 mutant-expressing HeLa cells were transfected with nonspecific, Gα 12 , Gα 13 , or Gα 12 and Gα 13 siRNAs and then stimulated with thrombin. Immunoblotting analysis indicates that siRNAs specifically depleted Gα 12 or Gα 13 protein in PAR1 WT and NA ECL2 cells (Fig. 3 A and B) . Thrombinactivated PAR1 WT caused a significant increase in RhoA activation in nonspecific siRNA control cells that was virtually abolished in cells depleted of either Gα 12 or Gα 13 proteins (Fig. 3A, lanes 5-8) . The modest increase in RhoA activation observed in thrombin treated PAR1 NA ECL2 siRNA transfected control cells was also significantly inhibited in Gα 12 and Gα 13 knockdown cells (Fig.  3B, lanes 5-8) . These findings indicate that PAR1-induced RhoA activation is dependent on G 12/13 proteins.
We next examined if PAR1 WT and NA ECL2 mutant showed differences in G 12/13 association using co-IP. HeLa cells stably expressing PAR1 WT and NA ECL2 mutant were transiently transfected with increasing amounts of Gα 12 plasmid. Cells were then stimulated with thrombin and immunoprecipitated, and the presence of coassociated Gα 12 protein was detected. PAR1 WT showed greater association with Gα 12 compared with NA ECL2 mutant basally when expressed at low levels (Fig. 4A , lanes 1-5 and 7-9) and after thrombin stimulation (Fig. 4A, lanes 6 and 10) . PAR1 WT also exhibited a preference for Gα 13 association compared with the NA ECL2 mutant both in the presence and absence of thrombin stimulation (Fig. S3) . Bioluminescence resonance energy transfer (BRET) measurement , lysed, and processed for GST-RBD pull-down assays, and activated RhoA was detected by immunoblotting. UT cells were processed similarly. The data (mean ± SD; n = 3) were normalized to total RhoA, are representative of three independent experiments, and were significant (*P < 0.05; ***P < 0.001). NS, not significant.
was also used to assess PAR1-Gα 12 association in living cells. COS-7 cells were transiently transfected with either full-length PAR1 WT or NA ECL2 mutant fused to YFP at the C terminus and Gα 12 -Rluc that yielded optimal expression (Fig. S4 ). Cells were then either left untreated or treated with thrombin, and the net BRET signal was quantified. Thrombin induced a statistically significant increase in the net BRET response elicited by PAR1 WT-YFP and Gα 12 -Rluc compared with untreated control cells (Fig. 4B) , suggesting that the activated PAR1 WT-Gα 12 complex undergoes a conformational change. In contrast, thrombin failed to induce a change in BRET signal in cells coexpressing PAR1 NA ECL2 and Gα 12 -Rluc (Fig. 4B ). These studies suggest that activation of PAR1 glycosylated at ECL2 results in a conformational state that preferentially couples to G 12/13 .
Glycosylation of PAR1 at ECL2 Does Not Affect G i Coupling or β-arrestin-1
Recruitment. In addition to G q and G 12/13 , PAR1 is known to signal through the G i protein in various cell types (1, 9) . To investigate whether glycosylation of PAR1 at ECL2 regulates coupling to G i , we examined PAR1-G i association by BRET. COS-7 cells were transiently transfected with a constant amount of Gα i -Rluc and increasing amounts of either PAR1 WT-YFP or NA ECL2-YFP, and the net BRET was determined. A hyperbolic increase in net BRET was observed as the ratio of PAR1 WT-YFP to Gα i -Rluc expression was increased (Fig. 5A) , suggesting a specific interaction. PAR1 NA ECL2-YFP and Gα i -Rluc saturation curves also yielded a hyperbolic increase in the net BRET signal (Fig. 5A) , suggesting that glycosylation of PAR1 at ECL2 does not affect basal association with G i protein. We next examined whether thrombin induced a change in PAR1-G i association. In COS-7 cells coexpressing equivalent amounts of either PAR1 WT-YFP or NA ECL2-YFP together with Gα i -Rluc (Fig. S5 A and B) , the addition of thrombin resulted in a rapid and transient increase in net BRET that peaked at 1 min and returned to baseline (Fig. 5B) . These findings indicate that activated PAR1 coupling to G i is not affected by glycosylation at ECL2. These results were confirmed by examining PAR1-Gα i association using co-IP. Activation of either PAR1 WT-YFP or NA ECL2-YFP with thrombin resulted in a marked fourfold increase in Gα iRluc association compared with untreated control cells (Fig. 5C) , consistent with the equal capacity of both PAR1 WT and NA ECL2 to associate with G i protein.
In addition to G proteins, many GPCRs display bias toward the multifunctional β-arrestin adaptor proteins (22) . Since the β-arrestin-1 isoform is the principal regulator of thrombin-activated PAR1 signaling (23, 24) , recruitment of β-arrestin-1 to PAR1 was examined by BRET. Intriguingly, PAR1 WT and NA ECL2 expressed at similar levels were equally effective at recruiting β-arrestin-1 following thrombin stimulation (Fig. 5 D and E and Fig. S5C ), indicating that glycosylation does not affect receptor-β-arrestin-1 association. Together, these data suggest that unlike G 12/13 and G q , PAR1 deficient in glycosylation at ECL2 displays no bias toward G i or β-arrestin-1. Quantifying PAR1 signaling bias. The operational model of agonism was next used to quantify the G-protein coupling bias of PAR1 WT versus NA ECL2 mutant (25, 26) . The concentrationresponse curves of G q -stimulated PI hydrolysis, G 12/13 -induced RhoA activation, and G i -activated PAR1 association (BRET) (Fig. S6) were normalized to receptor expression and fitted to the Black-Leff model of agonism to obtain the dissociation constant of the agonist-receptor complex (K A ) and an estimation of the τ transducer constant. The parameters τ and K A provide an approximation of the signal transduction efficiency and intrinsic agonist efficacy (Tables S1 and S2 ). The transduction coefficient for each pathway was then calculated as log (τ/K A ). To determine the relative bias of PAR1 NA ECL2 mutant to WT receptor, G i BRET response was used as the reference pathway, because G i displayed the least difference between WT and NA ECL2 mutant receptor. Each of the PAR1 WT and NA ECL2 mutant G-protein signaling assays were performed in the same cell type with comparable cell surface expression (Fig. S6) . To compare thrombin-induced G q and G 12/13 signaling pathway bias between the PAR1 WT and NA ECL2 mutant, the ΔΔlog(τ/K A ) was calculated (Table 1 and Fig.  S6 ). The calculated biases [ΔΔlog(τ/K A ) values] indicate that PAR1 NA ECL2 mutant is 0.58-fold less effective at coupling to the G 12/13 -RhoA pathway compared with WT receptor, whereas PAR1 NA ECL2 is 5.27-fold more effective at stimulating G q -induced PI hydrolysis than WT receptor. These findings strongly suggest that N-linked glycosylation of PAR1 at ECL2 regulates G 12/13 -versus G q -protein bias signaling. 12 and Gα 13 expression. FLAG-PAR1 WT (A) or NA ECL2 mutant (B) HeLa cells transfected with siRNAs were treated with 10 nM α-Th and processed for GST-RBD pull-down assays, and RhoA activation was determined. Cell lysates were immunoblotted as indicated. Data (mean ± SD; n = 3) are from three independent experiments and were significant (***P < 0.001).
Glycosylation-deficient endogenous PAR1 displays G-protein signaling bias. PAR1 is expressed in endothelial cells and signals through G q and G 12/13 to promote inflammatory responses (27) . To determine if glycosylation of endogenous PAR1 regulates G-protein signaling bias in human cultured endothelial cells, we used the pharmacological inhibitor tunicamycin, which blocks the first step in glycoprotein synthesis. Glycosylated PAR1 migrates as a broad ∼75-kDa protein that was reduced to its predicted molecular weight of ∼40 kDa following treatment with tunicamycin (Fig. 6A, lanes 3 and 5) , consistent with previous studies (18) . Tunicamycin also caused partial loss of PAR1 surface expression (Fig. S7A) ; however, the majority of the receptor trafficked to the cell surface. This was confirmed by examining PAR1's susceptibility to cleavage by thrombin at 4°C (18) , which caused a shift in the size of the major PAR1 species in both control and tunicamycin-treated cells (Fig. 6A, lanes 3-6) . In tunicamycin-treated endothelial cells expressing deglycosylated endogenous PAR1, thrombin induced a significantly greater increase in PI hydrolysis compared with control cells expressing the glycosylated native receptor (Fig. 6B) . In striking contrast, thrombin caused a marked response in RhoA activation under control conditions that was virtually ablated in cells treated with tunicamycin (Fig. 6C) . To ensure that tunicamycin does not globally affect cell signaling, epidermal growth factor (EGF)-induced ERK1/2 activation was examined and shown to be equivocal in control and tunicamycin-treated cells (Fig. S7B) . These findings provide evidence that N-linked glycosylation of PAR1 at ECL2 promotes enhanced G-protein-mediated PI signaling and diminished RhoA activation in a natural context.
PAR1 NA ECL2 Exhibits Reduced RhoA-Mediated Stress Fiber Formation
and Enhanced Cellular Proliferation. To test whether the effects of N-linked glycosylation on PAR1 differential coupling to G q versus G 12/13 impacts cellular responses, we examined actin stress fiber formation. Serum-deprived HeLa cells expressing PAR1 WT and NA ECL2 mutant were stimulated with thrombin, stained with phalloidin-TRITC to visualize F-actin filaments and imaged by confocal microscopy. Thrombin caused a marked increase in actin stress fiber formation in PAR1 WT cells (Fig. 7A) , whereas the response was significantly diminished in NA ECL2 cells (Fig.  7A) . Inhibition of RhoA activation with C3 toxin virtually abolished thrombin-induced actin stress fiber formation in PAR1 WT cells (Fig. 7B) , consistent with G 12/13 -induced RhoA-mediated stress fiber formation as previously reported (27) . These results suggest that N-linked glycosylation of PAR1 at ECL2 regulates preferential coupling to G 12/13 and induction of RhoA-mediated stress fiber formation.
Thrombin activation of PAR1 promotes G q -dependent mitogenic responses in fibroblasts (28, 29) . To determine if N-linked glycosylation of PAR1 at ECL2 affects thrombininduced cellular proliferation, [ 3 H]thymidine incorporation was measured to assess DNA synthesis in fibroblasts. In these studies, mouse lung fibroblasts derived from Par1 −/− gene knockouts stably expressing PAR1 WT or NA ECL2 mutant were deprived of serum and incubated with thrombin, and the amount of [ (Fig.  7C) , despite lower cell surface expression of PAR1 NA ECL2 compared with WT receptor (Fig. S7C) . Moreover, a substantially greater increase in [ 3 H]thymidine incorporation was observed in thrombin-stimulated PAR1 NA ECL2 fibroblasts relative to untreated control or WT fibroblasts (Fig. 7D) , whereas the cells responded equivocally to serum stimulation (Fig. 7D) . Together, these findings strongly suggest that N-linked glycosylation of PAR1 at ECL2 regulates preferential coupling to G 12/13 versus G q proteins, which modulate the robustness of thrombin-induced cellular responses in various cell types.
Discussion
In the present study, we define a novel function for N-linked glycosylation of a GPCR in regulation of G-protein signaling bias. A PAR1 mutant deficient in glycosylation at ECL2 favored coupling to G q -mediated PI signaling over G 12/13 -induced (A) FLAG-PAR1 WT or NA ECL2 HeLa cells transfected with Gα 12 -EE were treated with 10 nM α-Th, immunoprecipitated, and immunoblotted. Data (mean ± SD; n = 3) are from three independent experiments and were significant (*P < 0.05; **P < 0.01). (B) COS-7 cells cotransfected with PAR1 WT-YFP or NA ECL2-YFP and Gα 12 -Rluc were treated with 10 nM α-Th, and BRET was determined. Data shown (mean ± SD; n = 3) from three independent experiments were significant (**P < 0.01). NS, not significant.
RhoA activation, opposite of the glycosylated WT receptor. Moreover, endogenous PAR1 lacking glycosylation exhibited an enhanced G-protein-mediated PI response and reduced RhoA activation, in contrast to native receptor. Intriguingly, both PAR1 WT and mutant were equally effective at coupling to G i and β-arrestin-1. N-linked glycosylation of PAR1 at ECL2 also enhanced thrombin-induced RhoA-mediated stress fiber formation and attenuated cellular proliferation in fibroblasts, consistent with preferential coupling to G 12/13 versus G q proteins. These studies are the first, to our knowledge, to show that N-linked glycosylation of a GPCR is critical for G-protein coupling specificity.
The best described function for N-linked glycosylation of mammalian GPCRs is in proper folding of the nascent protein during translation and export to the cell surface. The majority ∼90% of Class A GPCRs contain N-linked glycosylation N-X-S/T consensus sequences within their N terminus, whereas only ∼30% of the receptors contain consensus sites within the extracellular loops (30) . The extent of glycosylation and full utilization of consensus sites likely varies with a given GPCR. PAR1 contains five consensus sites for N-linked glycosylation, three in the N terminus and two in ECL2, and all appear to be modified by glycosylation (18) . We previously showed that glycosylation of PAR1 at the N terminus and not the ECL2 is important for efficient transport to the cell surface (18) . In addition to cell surface export, other studies suggest a function for N-linked glycosylation in GPCR dimerization. N-linked glycosylation was shown to contribute to the stabilization of bradykinin-B2 receptor homodimerization (31), whereas β 1 -and α 2 -adrenergic receptor (AR) heterodimerization was inhibited by glycosylation (32) . Although PAR1 NA ECL2 appears largely as a monomer based on immunoblotting analysis (Figs. 1, 4 , and 5), a minor higher molecular weight species was sometimes evident. However, we failed to confirm a difference in PAR1 WT versus NA ECL2 mutant dimerization. Another study reported that N-linked glycosylation of the sphingosine-1-phosphate receptor effects caveolae localization (33) . Surprisingly, PAR1 distribution into caveolae was not affected by loss of glycosylation at ECL2 (Fig.  S1D) . Thus, these findings suggest that glycosylation of PAR1 at ECL2 likely serves a distinct function not related to surface export, dimerization, or partitioning into caveolae.
Glycosylation can also influence GPCR-ligand interactions. PAR2, a GPCR related to PAR1, is cleaved and activated by trypsin-like serine proteases but not by thrombin (1) . N-linked glycosylation of PAR2 at the N terminus was shown to affect tryptase but not trypsin cleavage (34) , indicating that glycosylation directly affects protease recognition and receptor activation. We previously showed that N-linked glycosylation of PAR1 at either the N terminus or ECL2 has no effect on the rate of receptor cleavage by thrombin (18) . Intriguingly, differential glycosylation of the gonadotrophin follicle-stimulating hormone (FSH) ligand modulates the capacity of the cognate FSH receptor to couple to G s versus G i signaling (35) . These findings indicate that naturally occurring heterogeneity of glycosylation of certain peptide hormones can affect GPCR-biased signaling. However, whether naturally occurring glycosylation of GPCRs affects G-protein signaling bias has not been previously reported.
Significant efforts have been made toward understanding the mechanisms by which certain GPCRs couple to multiple distinct G-protein subtypes in the same cell, but it remains poorly understood. Our results suggest that N-linked glycosylation of PAR1 at ECL2 regulates G-protein coupling specificity. The ECL2 of other class A GPCRs has also been shown to control ligand-directed effects (36, 37) . Thus, we hypothesize that N-linked glycosylation of PAR1 at ECL2 provides structural diversity that influences ligand-receptor interaction that favors coupling to G 12/13 versus G q proteins. The observed PAR1 WT and NA ECL2 mutant bias signaling is not due to alterations in expression of PAR1, G proteins, or intracellular effectors, because differential signaling was seen in the same cell types. In addition, the ΔΔLog(τ/K A ) index is a normalized number that takes into account differences in expression (26) . Specifically, the effects were expressed in terms of a reference pathway, namely, activation of G i protein where the mutation caused minimal effect (26) . Thus, our studies support a role for N-linked glycosylation in stabilization of a distinct active PAR1 state that selectively couples to G 12/13 over G q protein, but has no influence on receptor coupling to G i or β-arrestin-1. Prior studies showed a role for phosphorylation in isoproterenolstimulated β 2 -AR switching from G s to G i (38) . In this case, β 2 -AR initial coupling to G s is required for protein kinase A-mediated phosphorylation of ICL3 that promotes coupling to G i . In contrast to the β 2 -AR, we show that the existing status of PAR1 N-linked glycosylation before ligand stimulation is critical for specifying coupling to distinct G-protein subtypes.
Our studies suggest that PAR1 is likely to exist as an ensemble of active states that use different molecular determinants to couple to distinct G-protein subtypes that are stabilized in part by N-linked glycosylation at ECL2. Surprisingly, a role for glycosylation in modulating GPCR allostery and signaling has not been previously explored. The heterogeneity of glycosylation indicates that GPCRs are likely to exist as populations of receptors containing distinct glycan structures even when expressed in the same cell (39) . The contribution of these diverse structures to GPCR The operational model of agonism was used to quantify PAR1 WT versus NA ECL2 mutant bias toward G 12/13 -induced RhoA activation and G q -stimulated PI hydrolysis. The G i pathway exhibits the least bias and was designated as the reference pathway (ref.). The ΔΔlog(τ/K A ) value is a measure of the calculated bias for each pathway, with errors corresponding to 95% confidence interval (c.i.). Data (mean ± SD; n = 3) were normalized to PAR1 surface expression from three independent experiments and were significant (**P < 0.01). (C) Endothelial cells treated with or without TNC and 10 nM α-Th were processed for GST-RBD pull-down assays, and RhoA activation was determined. Data (mean ± SD, n = 4) were normalized to PAR1 surface expression and were significant (*P < 0.05).
function is not known. PAR1 is extensively glycosylated but the nature and diversity of N-glycan modification have not been determined. Importantly, naturally occurring mutations in N-linked glycosylation consensus sequences of Rhodopsin have been linked to retinitis pigmentosa (40, 41) , indicating that modulation of GPCR glycosylation status can contribute to disease progression. However, mutations in PAR1 N-linked glycosylation sites have not been identified. In summary, our findings demonstrate for the first time, to our knowledge, that N-linked glycosylation of a GPCR specifies coupling to distinct G-protein subtypes in the same cell.
Materials and Methods
Reagents and Antibodies. Human α-thrombin (α-Th) was from Enzyme Research Laboratories. SFLLRN was synthesized at Tufts University Core Facility. Insulin, transferrin, selenous acid (ITS) premix, caveolin-1, and anti-early endosomal antigen-1 (EEA1) antibodies were from BD Biosciences. ERK1/2 antibodies were from Cell Signaling Technologies. C3 transferase toxin was from Cytoskeleton, Inc. Polyclonal and M2 monoclonal anti-FLAG antibody, TRITC-conjugated phalloidin, tunicamycin, EGF, and anti-β-actin antibody were from Sigma. The anti-PAR1 WEDE antibody was from Beckman Coulter. Anti-PAR1 polyclonal antibody was generated against the YEPFWE-DEEKNESGLTEYC peptide. RhoA, Gα q/11 , Gα 12 , and Gα 13 antibodies were from Santa Cruz Biotechnology. Renilla Luciferase antibody was from Millipore. Horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit antibodies were from Bio-Rad Laboratories.
cDNAs and Cell Lines. HeLa cells stably expressing N-terminal FLAG-tagged PAR1 WT and NA ECL2 were generated as described in ref. 18 . HA-Gα q plasmid was from Philip Wedegaertner, Thomas Jefferson University, Philadelphia, PA. Gα 12 -EE and Gα 13 -EE constructs were from Dr. John Hepler, Emory University, Atlanta, GA. Gα i -Rluc, Gα 12 -Rluc, Gα 13 -Rluc, and PAR1-YFP plasmids were from Dr. Jean-Philippe Pin, Montpellier University, Montpellier, France. PAR1-YFP NA ECL2 mutant was generated by site-directed mutagenesis using the QuikChange Mutagenesis kit (Stratagene) and confirmed by dideoxy sequencing. COS-7, HeLa, and endothelial cells were cultured as described in refs. 18, 21, and 42. Fig. 7 . PAR1 NA ECL2 exhibits diminished stress fiber formation and enhanced cellular proliferation. (A) FLAG-PAR1 WT or FLAG-NA ECL2 mutant HeLa cells were treated with 10 nM α-Th for 5 min, stained with phalloidin-TRITC, and imaged. Data (mean ± SD; n = 3) for f-actin fluorescence were quantified from four different images of three independent experiments and were significant (*P < 0.05). (Scale bar, 10 μm.) (B) FLAG-PAR1 WT HeLa cells pretreated with 1.5 μg/mL C3 toxin for 4 h at 37°C or DMSO were incubated with 10 nM α-Th for 5 min and stained with phalloidin-TRITC, and f-actin fluorescence was quantified. Data (mean ± SD; n = 3) were significant (***P < 0.001). (Scale bar, 10 μm.) (C) Mouse lung fibroblasts expressing FLAG-PAR1 WT or NA ECL2 mutant were incubated without (basal) or (D) with 10 nM α-Th or 2% FBS, and [ 3 H]thymidine incorporation was measured. Basal [ 3 H]thymidine incorporation (mean ± SD; n = 3) is from three independent experiments and was significant (***P < 0.001). Data (mean ± SD; n = 3) are from α-Th-stimulated [ 3 H]thymidine incorporation from three independent experiments and were significant (*P < 0.05). NS, not significant.
